Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating properties. These effects may be responsible for dasatinib's unique side effects including a distinctive form of hemorrhagic colitis. We report a case of hemorrhagic colitis associated with dasatinib use in a patient with chronic myelogenous leukemia. Colon biopsies at the time of symptomatic colitis confirmed CD3+CD8+ T cell infiltration. The process rapidly resolved following drug discontinuation, but relapsed when rechallenged with a reduced dose of dasatinib. Colitis did not recur when the patient was treated with an alternative agent. A literature review of prior cases involving dasatinib-induced T-cell mediated colitis provides insight into commonalities that may facilitate the recognition and management of this entity. Most incidences occurred after a 3-month drug exposure and may be accompanied by large granular lymphocytes. The process uniformly resolves within a few days following drug discontinuation and will generally recur in a shorter period of time if the drug is reintroduced. Most patients will require an alternative agent, although select patients could be continued on dasatinib if other options are limited.

Keywords:
Dasatinib, Hemorrhagic colitis, T cells
1.
Lombardo L, Lee FY, Chen P, Norris D, Barrish J, Behnia K, Castaneda S, Cornelius L, Das J, Doweyko A, Fairchild C, Hunt J, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven G, Schmidt R, Tokarski J, Wen M, Wityak J, Borzilleri R: Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
2.
Fabian M, Biggs W III, Treiber D, Atteridge C, Azimioara M, Benedetti M, Carter T, Ciceri P, Edeen P, Floyd M, Ford J, Galvin M, Gerlach J, Grotzfeld R, Herrgard S, Insko D, Insko M, Lai A, Lélias J, Mehta S, Milanov Z, Velasco A, Wodicka L, Patel H, Zarrinkar P, Lockhart D: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-336.
3.
Rix U, Hantschelk O, Dürnberger G, Remsing-Rix L, Planyavsky M, Fernback N, Kaupe I, Bennett K, Valent P, Colinge J, Köcher T, Superti-Furga G: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-4063.
4.
Hochhaus A, Kantarjian H: The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 2013;139:1971-1984.
5.
Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R: Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-359.
6.
Quintas-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J: Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115:2482-2490.
7.
Kantarjian H, Shah N, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué, Chuah C, Bleickardt E, Bradley-Garelik M, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
8.
Santos F, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J: Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 2010;150:303-312.
9.
Jabbour E, Kantarjian H, Saglio G, Steegmann J, Shah N, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim D, Bradley-Garelik M, Mohamed H, Wildgust M, Hocchaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
10.
Mustjoki S, Ekblom M, Arstila T, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann J, Stenke L, Porkka K: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
11.
Shimokaze T, Mitsui T, Takeda H, Kawakami T, Arai T, Ito M, Iwaba A, Izumino H, Takahashi N, Kanno M, Sendo D, Hayasaka K: Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Hematol Oncol 2009;26:448-453.
12.
Ono Y, Mori T, Kato J, Yamane A, Yajima T, Iwao Y, Hibi T, Okamoto S: Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia. Int J Hematol 2010;92:556-558.
13.
Erkut M, Erkut N, Ersoz S, Arslan M, Sonmez M: A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta Haematol 2010;123:205-206.
14.
Sunami Y, Sato E, Ichikawa K, Yasuda H, Komatsu N: Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase. Rinsho Ketsueki 2011;52:282-286.
15.
Patodi N, Sagar N, Rudzki Z, Langman G, Sharma N: Haemorrhagic colitis caused by dasatinib. Case Rep Hematol 2012;2012:417106.
16.
Chisti MM, Khachani A, Brahmanday G, Klamerus J: Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis. BMJ Case Rep 2013;2013:200610.
17.
Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K: Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013;4:59-62.
18.
Saito M, Izumiyama K, Mori A, Irie T, Tanaka M, Morioka M, Saga A, Musashi M, Kato T, Meguro T, Tanino M: Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Rinsho Ketsueki 2014;55:130-132.
19.
Eskazan AE, Hatemi İ, Öngören Aydın S, Ar MC, Soysal T: Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. Turk J Gastroenterol 2014;25(suppl 1):233.
20.
Yassin M, Nashwan A, Soliman A, Yousif A, Moustafa A, AlBattah A, Mohamed S, Mudawi D, Elkourashy S, Asaari D, Gutierrez H, Almusharaf M, Hussein R, Moustafa A, Derhoubi H, Boukhris S, Kohla S, AlDewik N: Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy. Clin Med Insights Case Rep 2015;8:77-81.
21.
Hoshino T, Tahara K, Kohta M, Hatsumi N, Takada S, Shuichi M, Sakura T: Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib. Rinsho Ketsueki 2010;51:191-188.
22.
Quintás-Cardama A, Han X, Kantarjian H, Cortes J: Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263.
23.
Kim D, Kamel-Reid S, Chang H, Sutherland R, Jung C, Kim H, Lee J, Lipton J: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135-139.
24.
Valent JN, Schiffer CA: Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011;35:e1-e3.
25.
Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S: Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-782.
26.
Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen A, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee F, Vakkila J, Jalkanen S, Salmi M, Porkka K: Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013;27:914-924.
27.
Steegmann J, Cervantes F, le Coutre P, Porkka K, Saglio G: Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53:2351-2361.
28.
Buchdunger E, Cioffi C, Law N, Stover D, Ohno-Jones S, Druker B, Lydon N: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
29.
Kantarjian H, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele G, Nicolini F, O'Brien S, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta D, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.
30.
Pfizer (communication).
31.
Schade A, Schieven G, Townsend R, Jankowska A, Susulic V, Zhang R, Szpurka H, Maciejewski J: Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366-1377.
32.
Blake S, Hughes T, Mayrhofer G, Lyons A: The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008;127:330-339.
33.
Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell A, Zezula J, Greiner E, Price D, Einsele H, Seggewiss R: Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14:2484-2491.
34.
Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price D, Mustjoki S, Seggewiss R: Expansion of highly differentiated CD8+ T-cells or NK-cells in patients with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587-1597.
35.
Fei F, Yingzhe Y, Schmitt A, Rojewski M, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M: Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol 2009;144:195-205.
36.
Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M: Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood. Blood 2012;119:6175-6176.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.